The autosampler vials available from the Biolabs stockroom get cored by the autosampler needle. Please do not use these vials for sample submission. Get alternative autosampler vials with rubber septa.
The Bruker Impact q-TOF will undergo a significant hardware upgrade and become a Impact HD on Monday February 3 and February 4 . This upgrade involves the installation of a more powerful turbo pump for better vacuum, and the change of the digitizer from a 8 bit to a 10 bit board. What this means for us is that we will now have significantly higher dynamic range, and better sensitivity for proteins. The detector will not saturate as easily with concentrated samples, letting us see the low level components in a complex mixture. Read more about Upgrade for the Bruker q-TOF
If you have data from our Bruker q-TOF Impact and want to view the data, ask Sunia about the DA Viewer license free version. She can help you set it up on your computer. Also, DA Viewer has now been placed on the computer adjacent to the Agilent ESI-TOF for data viewing so you can use it to view your Bruker data.
Due to the heavy demand for the ESI-TOF for high resolution work, we have decided to leave a two hour block open daily between 10 AM to 12 PM. During this time, you can run quick flow injection analysis (direct injection/no LC) experiments by using the Easy Access software. This ensures a time every day where people can do simple high resolution work. Easy Access queues up samples so it is first-come-first serve!
Due to heavy use of the Agilent ESI-TOF, some people were not able to run their quick direct injection experiments on certain days. While many of you would probably like a dedicated "open access" instrument, this is not possible or an efficient use of the instrument, since on some days, no one runs their samples. Our alternate solution, I believe will assure a more efficient use of the instrument, while still allowing people to run their quick samples daily. Read more about NEW Open Access Hours 10-12pm for Quick Experiments
Congratulations to Henry Haiser, Peter Turnbaugh and our own Kelly Chatman for their manuscript in the journal Science entitled "Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta". Kelly's project with Henry involved the targeted quantification of the cardiac drug digoxin, and its metabolites to discover how differences in gut microbiome can affect drug metabolism (Science, July 19th 2013, Vol. 341, 6143, pp. 295-298).